Phase 1 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose overall health and ability to carry out daily activities meets a certain minimum level, as measured by a standard oncology scoring system (confirm with trial site)
- People who have had their prostate cancer confirmed by a tissue or cell sample as a type called adenocarcinoma; those with a mixed tumour type may still be eligible as long as the non-adenocarcinoma part is the smaller portion
- People who have at least one area where cancer has spread to other parts of the body, confirmed by a CT scan, MRI, or bone scan taken within 28 days before the trial starts
- People whose testosterone levels in the blood are at a very low "castrate" level, below a specific threshold
- People who are receiving ongoing hormone-blocking treatment for prostate cancer, either through surgical removal of the testicles or through ongoing hormone-suppressing medication
- People whose cancer has continued to grow despite other standard treatments, or for whom other standard treatments are not suitable; previous treatment with taxane chemotherapy, PARP inhibitor drugs, or a treatment called lutetium-177 PSMA therapy (Pluvicto) is permitted
- For a specific part of the trial involving a combination treatment, people must not have previously received any treatment specifically for cancer that has spread while remaining hormone-resistant (confirm with trial site)
Who may not be able to join:
- People under 18 years of age
- People whose prostate cancer has been confirmed as a type other than adenocarcinoma
- People whose cancer has only shown up in blood test results without any visible spread to other parts of the body on imaging scans
- People who have previously been treated with a specific class of drugs called cereblon-based degraders
- People who are HIV-positive or have a weakened immune system
- People who are taking medications known to affect the heart's electrical rhythm in a specific way, unless those medications can be stopped for the entire duration of the trial
- People who have received another experimental treatment within 7 days, or within 5 half-lives of that drug (whichever is the longer period), before the trial start date
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-888-669-6682
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence and severity of dose-limiting toxicities (DLTs); Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs); Frequency of dose interruptions and reductions; Dose intensity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.